Identification of the RelA domain responsible for action of a new NF-κB inhibitor DHMEQ

Biochemical and Biophysical Research Communications

Volumn 376, Issue 2, 2008, Pages 310-314

  Watanabe, Mariko ^a   Nakashima, Makoto ^a   Togano, Tomiteru ^a   Higashihara, Masaaki ^a   Watanabe, Toshiki ^b   Umezawa, Kazuo ^c   Horie, Ryouichi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Graduate School of Frontier Sciences   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

DHMEQ; NF B inhibitor; p50; RelA

Indexed keywords

CYSTEINE; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; HELA CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION;

AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL NUCLEUS; CYCLOHEXANONES; CYSTEINE; HELA CELLS; HUMANS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION; TRANSCRIPTION FACTOR RELA;

MAMMALIA;

EID: 52949115652     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.148     Document Type: Article

References (18)

1. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S., Inoue J., and Umezawa K. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10 (2000) 865-869
2. Gilmore T.D. Introduction to NF-κB: players, pathways, perspectives. Oncogene 25 (2006) 6680-6684
3. Basseres D.S., and Baldwin A.S. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 25 (2006) 6817-6830
4. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci. 97 (2006) 990-995
5. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 277 (2002) 24625-24630
6. Watanabe M., Dewan M.Z., Okamura T., Sasaki M., Itoh K., Higashihara M., Mizoguchi H., Honda M., Sata T., Watanabe T., Yamamoto N., Umezawa K., and Horie R. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer 114 (2005) 32-38
7. Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., Utsunomiya A., Koga S., Yamada Y., Kamihira S., Okayama A., Kikuchi H., Uozumi K., Yamaguchi K., Higashihara M., Umezawa K., Watanabe T., and Horie R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106 (2005) 2462-2471
8. Kunkel T.A., Bebenek K., and McClary J. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 204 (1991) 125-139
9. Smith D.B., and Johnson K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67 (1988) 31-40
10. Hoffmann A., Natoli G., and Ghosh G. Transcriptional regulation via the NF-κB signaling module. Oncogene 25 (2006) 6706-6716
11. Latimer M., Ernst M.K., Dunn L.L., Drutskaya M., and Rice N.R. The N-terminal domain of IκBα masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol. Cell. Biol. 18 (1998) 2640-2649
12. Guan H., Hou S., and Ricciardi R.P. DNA binding of repressor nuclear factor-κB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J. Biol. Chem. 280 (2005) 9957-9962
13. Matsumoto G., Namekawa J., Muta M., Nakamura T., Bando H., Tohyama K., Toi M., and Umezawa K. Targeting of nuclear factor κB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 11 (2005) 1287-1293
14. Dejardin E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72 (2006) 1161-1179
15. Garcia-Pineres A.J., Castro V., Mora G., Schmidt T.J., Strunck E., Pahl H.L., and Merfort I. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 276 (2001) 39713-39720
16. Garcia-Pineres A.J., Lindenmeyer M.T., and Merfort I. Role of cysteine residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci. 75 (2004) 841-856
17. Liang M.C., Bardhan S., Porco Jr. J.A., and Gilmore T.D. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IκBα-deficient diffuse large B-cell lymphoma cell line. Cancer Lett. 241 (2006) 69-78
18. Harhaj E.W., and Sun S.C. Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol. Cell. Biol. 19 (1999) 7088-7095